Guardant Health Says Stock Trading Temporarily Halted As FDA Panel To Assess Premarket Approval Application For Shield Blood Test For Colorectal Cancer Screening
Portfolio Pulse from Benzinga Newsdesk
Guardant Health's stock trading has been temporarily halted as the FDA's Molecular and Clinical Genetics Panel reviews the premarket approval application for Shield, a blood test for colorectal cancer screening.
May 23, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Guardant Health's stock trading has been temporarily halted as the FDA reviews the premarket approval application for Shield, a blood test for colorectal cancer screening.
The temporary halt in trading is a neutral event in the short term as it is a procedural step. The outcome of the FDA panel's review will determine the future impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100